Oleanzrapitab 10 Sun Pharma tablets treat schizophrenia (5 blisters x 10 tablets)

Dosage form Box of 5 blisters x 10 tablets
Specifications Olanzapine

Ingredient

Composition information	Content
Olanzapine	10mg

Uses

Indications

Oleanzrapitab drug are indicated in the following cases:

Treatment of diseases schizophrenia . Olanzapine is effective in maintaining the improvement of clinical symptoms while continuing treatment in patients who respond to the initial treatment. Nm, in order), dopamine d1 - 4 (ki = 11 - 31 nm), histamine h1 (ki = 7 nm), and adrenergic receptors α1 (ki = 19 nm). Olanzapine is an antagonist with an average cohesion affair with 5HT3 collection (Ki = 57 olanzapine loosely connected with GABAA, BZA and β - adrenergic receptors (KI> 10 μm).

The antagonism in dopamine and 5HT2 receptors can explain some olanzapine therapies and side effects. The antagonism of olanzapine of Muscarinic M1 - 5 receptors can explain the effects similar to its cholinergic resistance. Olanzapine H1 H1 receptor antagonists can explain the phenomenon of sleeping chicken observed with this drug. The antagonism of Adrenergic receptors α1 can explain the effect of hypotension that can be observed with this drug

pharmacokinetic pharmacokinetics

absorption and distribution

Used orally, olanzapine monomers are well absorbed and reach peak concentration for about 6 hours after taking a dose of oral. It is excreted throughout the body by α chemical through the liver for the first time, with about 40% of the dose metabolized before entering the circulatory system. Olanzapine manifests linear dynamics on clinical dose. The sale period is from 21 to 24 hours, and the serum purification is from 12 - 47L/hour.

Use olanzapine once a day to create a stable concentration after about 1 week and this concentration is about 2 times the concentration after the single dose. Serum concentration, sale time and purification of olanzapine may vary between individuals based on smoking, gender and age. Olanzapine is widely distributed throughout the body, with an integral distribution of about 1000L. There are about 93% combined with serum protein on a concentration of 7 to 1100 ng/ml, mainly linked to albumin and α1 - Glycoprotein acid.

Metabolism and elimination

After a single dose of olanzapine dose marked 14C, 7% of olanzapine dose found in urine in the form of constant, showing that olanzapine is highly metabolized. About 57% and 30% of the dose are found in urine and feces, in order. In serum, olanzapine only accounts for 12% of AUC for the total number of radioactive, showing a significant presence of metabolites.

After using multiple doses, the main metabolites within the circulatory are 10 - N - Glucuronide, present in a stable state at 44% of olanzapine concentrations, and 4 ' - n - desmethylanzapine, present in a stable state at 31% of olanzapine concentrations. Both metabolites have no pharmacological effects at observation concentration. Direct glucuronic and indirect oxidation Cytochrome P450 (CYP) are the main metabolic lines of olanzapine.

In vitro research shows that CYPS 1A2, 2D6 and Monoxygenase enzyme system containing Flavin are involved in the oxidation of olanzapine. The indirect oxidant in vivo in vivo is present to perform secondary metabolic lines, because the purification of olanzapine is not reduced in these enzyme deficiency objects.

Before taking Oleanzrapitab 10 Sun Pharma tablets treat schizophrenia (5 blisters x 10 tablets)

How to use

Oral drugs.

Dosage

oleanzrapitab should be used once a day and is not related to meals, usually used at a dose of 5 - 10 mg, with the desired dose of 10 mg/day for a few days. Additional dose adjustment if indicated, usually occurs between doses and not less than 1 week. The daily dose can then be adjusted according to the clinical disease of each patient with a material of 5 - 20 mg/day. Increasing the dose is 10mg/day higher than the dose of treatment, for example, 15 mg/day or higher is only proposed after the clinical reassessment appropriately.

Children

oleanzrapitab has not been studied in humans

Older patients

Low starting dose (5 mg/day) is not usually indicated but considered for 65 -year -old patients or more when there are clinical warning factors.

Patients with reduced liver or kidney function

Low starting dose (5 mg/day) can be considered for these patients.

Female patients compared to male patients

The starting dose and the interval does not need to change regularly for female patients relatively compared to male patients.

Patients who do not smoke compared to smoking patients

The starting dose and the dose does not need to change regularly for patients who do not smoke to smokers. When there is a factor that can slow down the metabolic process (women, older patients, non -smoking), the consideration should be set to reduce the starting dose. The escalation dose, when indicated, should be used carefully in these patients.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when using overdose?

Symptoms

In patients, the largest amount is determined, 300 mg, only reported symptoms of sleeping, stuttering. The limitations of patients are assessed at hospitals, including patients taking a dose of 300mg, there is no sign that there is an adverse change in laboratory analysis or ECGS.

Signs of life are usually within normal limits when overdose. Based on animal data, symptoms are expected to overdue the known pharmacological effects of the drug. These symptoms may include chickens, pupils, blurred vision, respiratory failure, hypotension and may be disturbed.

Treatment

There is no specific antidote for olanzapine, so the appropriate support measures should be started. It is necessary to consider the possibility of a combination of many other drugs. In case of acute overdose, setting and maintaining airway and must ensure adequate oxygen and ventilation.

The use of activated carbon overdose should be considered because the use of activated carbon has shown to reduce the bioavailability of olanzapine 50 - 60%. Stomach lavage (after placing the trachea tube, if the patient is unconscious) may also be considered.

Hypotension and shock should be treated with appropriate measures, such as intravenous fluids or sympathetic stimulants such as norepinephrine (not using epinephrine, dopamine or sympathetic stimulants different from beta antagonism because beta stimulation can worsen blood pressure lowering). Cardiovascular monitoring should be considered to detect the possibility of arrhythmia. Continue to monitor and monitor closely until the patient recovers.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using oleanzrapitab drugs , you may experience unwanted effects (ADR).

Common (10%)

Sleep and weight gain is the only common side effect when using olanzapine. Weight gain is associated with body index (BMI) before treatment and the starting dose is 15 mg/day or higher.

Uncommon (1 - 10%)

Dizziness , increased appetite, peripheral edema, posture hypotension, and fleeting cholinergic resistance, mild level including fertilization, dry mouth are less common side effects when using olanzapine.

Increasing AST liver enzymes, asymptomatic, fleeting Alt are also rare, especially in the early stages of treatment. Although there are different studies on olanzapine in the treatment of patients with lower Parkinson's incidence, Akaithisia, and muscle tone disorders compared to the dose are standardized according to Haloperidol. When there is no detailed information about the history of acute and chronic dysfunction in each patient, it is impossible to conclude that olanzapine is less likely to cause slow rhythmic disorders or other extracurricular syndrome.

Rare (

Rare also has a light sensitive symptom that has been reported. In most patients, this prolactin level can return to normal without stopping treatment.

High concentration of Creatine Phosphokinase enamel is also recorded in rare cases. Like other sedative drugs, the asymptomatic hematological changes are also rarely seen.

Instructions on how to handle ADR

Notify the doctor with unwanted effects when using.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Oleanzrapitab drug contraindicated in the following cases:

Patients who already know hypersensitivity to any ingredients of the drug.

Patients who know the risk of glaucoma narrow angle.

Precautions when using

Patients with combined disease:

olanzapine proved to have a low rate of cholinergic resistance in clinical studies. Precautions should be carefully prescribed in patients with prostate hypertrophy, or semi -circuit intake and related cases because of clinical experience when treating olanzapine limited to accompanying patients.

Increasing liver enzymes, ALT, AST transient, no clinical symptoms occasionally noticed especially in the early stages of treatment. Caution should be used in patients with AST or ALT liver enzymes, in patients with symptoms of liver function reduction, patients are available with the accompanying disease with a limited reserve of liver function, and on patients treated with liver toxic drugs. When an increase in AST or ALT liver enzymes during treatment, it is necessary to monitor and reduce the dose if necessary.

As well as other sedatives, cautious when used for patients with leukemia or polygon leukemia for any reason, patients who have a history of pulp or medulla due to drugs, patients with bone marrow inhibitor due to the accompanying pathogens, radiation or chemotherapy and on patients with hyperlypes of multi -kindness or bone marrow hyperbols. These 32 patients have neutropeniasis due to clozapin or have a history of granulocytes due to the use of oleanzapine without reducing neutrophilic leukemia compared to normal levels.

Malignant syndrome caused by sedatives (NMS):

NMS, a complex of symptoms at risk of death, have been reported related to other anti -psychotic drugs. In clinical studies, no MNS cases are reported in patients treated with olanzapine.

NMS is often accompanied by symptoms of fever, muscle spasticity, mental change, evidence of unconscious insecurity (vessels or abnormal blood pressure, tachycardia, sweating, and heartbeat disorders). Other signs may include increased creatine phosphokinase, myoglobin urinary (ureter muscle), and acute renal failure. Or high fever in unexplained and no clinical symptoms of NMS, all sedatives, including olanzapine, need to stop immediately.

olanzapine should be used carefully in patients with epilepsy or seizures related to seizures.

Slow pacemaker: Olanzapine often comes with a statistical proportion in the treatment of dysfunction arising in comparative studies that last for 1 year or less. However, the risk of slow -pacing disorder increases with prolonged contact time, and so if there are signs and symptoms of slow -pacemaking disorder occurring in patients using olanzapine, the dose reduction or stop use.

These symptoms may reduce the effect of temporary or even arise after treatment. Precautions when taking olanzapine in patients with treatment in combination with other central and alcoholic drugs (stated in the central nervous effects of olanzapine). When there is an expression of dopamine's opposition, olanzapine may be opposed to direct and indirect effects on dopamine. Hypotension does not usually occur in older patients using olanzapine in clinical studies. Like other mental medications, it is necessary to measure blood pressure periodically in patients> 65 years old.

In clinical studies, olanzapine should not be used for patients with abnormal increase in qt on the electrocardiogram. However, like other mental medications, it is necessary to be cautious when taking olanzapine with known drugs that increase the QTC, especially in older patients.

The ability to drive and operate machinery

olanzapine is likely to cause drowsiness, patients should be carefully advised when operating dangerous machines, including motorcycles.

Pregnancy

There are no well -controlled and complete studies in pregnant women. Patients should be advised to notify physicians if they are pregnant or intend to get pregnant during treatment with olanzapine. However, because the experience of using drugs in humans is not enough, this drug should only be used for pregnant women only when the benefits achieve higher than the risk of harmful to the fetus.

Breastfeeding period

olanzapine is excreted in the mouse's milk for medication during breastfeeding. It is not known whether olanzapine will be excreted in human milk. Patients should be advised not to breastfeed if they are taking olanzapine.

Drug interaction

The possibility of other drugs that can affect olanzapine:

Single dose of antacids (Al, Mg) or cimetidine does not affect the biological activity of oral olanzapine. Using at the same time with activated carbon can reduce the biological activity of olanzapine oral to 50 - 60%. Olanzapine's metabolism may be reduced when there is an accompanying smoking (olanzapine's clearance is 33% lower and the half -life of removal of drugs is longer than 21% in non -smokers compared to smokers) or carbamazepine treatment (the clearance increases to 44% and the sale time of removal of 20% reduced drugs when used with carbamazepine). Smoking and carbamazepine treatment reduces the activity ofp450 - 1A2.

The pharmacokinetics of theophyllline, metabolized by P450 - 1A2, does not change by olanzapine. The impact of P450-1A2 activity inhibitors on pharmacokinetics of olanzapine has not been studied.

Olanzapine's impact ability on other drugs: olanzapine does not inhibit the metabolism of imipramine/desipramine (P450 - 2D6 or P450 - 3A1/A2), Warfarin (P450 - 299), Theophylline P450 - 1A2), or Diazepam (P450 - 3A4 and P450 - 2019). Olanzapine does not give interactions when used in combination with lithium or biperiden.

Storage

Store drugs below 30 ° C, in a cool, dry place, avoid light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.